A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Elritercept
DRUG: Placebo

Sponsor

Takeda